Article
Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
Thoracic cancer - 1 Jan 2020
Hayakawa Daisuke, Takahashi Fumiyuki, Mitsuishi Yoichiro, Tajima Ken, Hidayat Moulid, Winardi Wira, Ihara Hiroaki, Kanamori Koichiro, Matsumoto Naohisa, Asao Tetsuhiko, Ko Ryo, Shukuya Takehito, Takamochi Kazuya, Hayashi Takuo, Suehara Yoshiyuki, Takeda Nakamura Ikuko, Ueno Toshihide, Kohsaka Shinji, Mano Hiroyuki, Takahashi Kazuhisa
Abstract excerpt
BACKGROUND: Osimertinib (AZD9291) is a third-generation EGFR-tyrosine kinase inhibitor (TKI) that selectively inhibits the activating EGFR mutation and T790M mutation, and is currently used globally to treat EGFR-mutant non-small cell lung cancer (NSCLC). However, acquired resistance to osimertinib is inevitable. METHODS: We established osimertinib-resistant cells (PC9/T790M/AZDR and H1975/AZDR) derived from...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.